Optimization of epicutaneous immunization for the induction of CTL

Vaccine

Volumn 21, Issue 21-22, 2003, Pages 2890-2899

  Kahlon, Roopjeet ^a   Hu, Yuxiang ^a   Orteu, Catherine H ^a   Kifayet, Arnawaz ^a   Trudeau, Jacqueline D ^a,b   Tan, Rusung ^a   Dutz, Jan P ^a,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b SIMON FRASER UNIVERSITY   (Canada)

^c Skin Care Center   (Canada)

Author keywords

CTL; Dendritic cells; Skin

Indexed keywords

CHOLERA TOXIN; IMMUNOGLOBULIN G2A; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; OVALBUMIN;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGEN ANTIBODY REACTION; ANTIGEN SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; IMMUNIZATION; LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN INJURY;

EID: 0038381565     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00141-5     Document Type: Article

References (58)

1. Boon T., Cerottini J.C., Van den Eynde B., van der Bruggen P., Van Pel A. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12:1994;337-365.
2. Bangham CRM, McMicahel AJ. T cell immunity to viruses. In: Feldmann M, Lamb J, Owen MJ, editors. T cells. New York: Wiley; 1989. p. 281-310.
3. Steinman R.M., Pope M. Exploiting dendritic cells to improve vaccine efficacy. J. Clin. Invest. 109(12):2002;1519-1526.
4. Banchereau J., Steinman R.M. Dendritic cells and the control of immunity. Nature. 392(6673):1998;245-252.
5. Fong L., Engleman E.G. Dendritic cells in cancer immunotherapy. Annu. Rev. Immunol. 18:2000;245-273.
6. Grabbe S., Bruvers S., Gallo R.L., Knisely T.L., Nazareno R., Granstein R.D. Tumor antigen presentation by murine epidermal cells. J. Immunol. 146(10):1991;3656-3661.
7. Celluzzi C.M., Falo L.D. Jr. Epidermal dendritic cells induce potent antigen-specific CTL-mediated immunity. J. Invest. Dermatol. 108(5):1997;716-720.
8. Bergstresser P.R., Fletcher C.R., Streilein J.W. Surface densities of Langerhans cells in relation to rodent epidermal sites with special immunologic properties. J. Invest. Dermatol. 74(2):1980;77-80.
9. Glenn G.M., Rao M., Matyas G.R., Alving C.R. Skin immunization made possible by cholera toxin. Nature. 391(6670):1998;851.
10. Glenn G.M., Scharton-Kersten T., Vassell R., Mallett C.P., Hale T.L., Alving C.R. Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. J. Immunol. 161(7):1998;3211-3214.
11. Glenn G.M., Scharton-Kersten T., Vassell R., Matyas G.R., Alving C.R. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants. Infect. Immun. 67(3):1999;1100-1106.
12. Seo N., Tokura Y., Nishijima T., Hashizume H., Furukawa F., Takigawa M. Percutaneous peptide immunization via corneum barrier-disrupted murine skin for experimental tumor immunoprophylaxis. Proc. Natl. Acad. Sci. U.S.A. 97(1):2000;371-376.
13. Shaw J, Provo M, Gale R, Yum S. Percutaneous absorption. In: Goldsmith L, editor. Physiology, biochemistry and molecular biology of the skin. New York: Oxford University Press; 1991. p. 1447-79.
14. Nishijima T., Tokura Y., Imokawa G., Seo N., Furukawa F., Takigawa M. Altered permeability and disordered cutaneous immunoregulatory function in mice with acute barrier disruption. J. Invest. Dermatol. 109(2):1997;175-182.
15. Magram J., Connaughton S.E., Warrier R.R.et al. IL-12-deficient mice are defective in IFN gamma production and type 1 cytokine responses. Immunity. 4(5):1996;471-481.
16. Carbone F.R., Bevan M.J. Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo. J. Exp. Med. 171(2):1990;377-387.
17. Altman J.D., Moss P.A., Goulder P.J.et al. Phenotypic analysis of antigen-specific T lymphocytes. Science. 274(5284):1996;94-96.
18. Saloga J., Renz H., Larsen G.L., Gelfand E.W. Increased airways responsiveness in mice depends on local challenge with antigen. Am. J. Respir. Crit. Care Med. 149(1):1994;65-70.
19. Ruedl C., Koebel P., Bachmann M., Hess M., Karjalainen K. Anatomical origin of dendritic cells determines their life span in peripheral lymph nodes. J. Immunol. 165(9):2000;4910-4916.
20. Babiuk S., Baca-Estrada M., Babiuk L.A., Ewen C., Foldvari M. Cutaneous vaccination: the skin as an immunologically active tissue and the challenge of antigen delivery. J. Control Release. 66(2-3):2000;199-214.
21. Gockel C.M., Bao S., Beagley K.W. Transcutaneous immunization induces mucosal and systemic immunity: a potent method for targeting immunity to the female reproductive tract. Mol. Immunol. 37(9):2000;537-544.
22. Hammond S.A., Walwender D., Alving C.R., Glenn G.M. Transcutaneous immunization: T cell responses and boosting of existing immunity. Vaccine. 19(17-19):2001;2701-2707.
23. Beignon A.S., Briand J.P., Muller S., Partidos C.D. Immunization onto bare skin with heat-labile enterotoxin of Escherichia coli enhances immune responses to coadministered protein and peptide antigens and protects mice against lethal toxin challenge. Immunology. 102(3):2001;344-351.
24. + T cells, respectively, mediate and regulate contact sensitivity to dinitrofluorobenzene. Eur. J. Immunol. 25(11):1995;3006-3010.
25. Rotzschke O., Falk K., Stevanovic S., Jung G., Walden P., Rammensee H.G. Exact prediction of a natural T cell epitope. Eur. J. Immunol. 21(11):1991;2891-2894.
26. Udaka K., Wiesmuller K.H., Kienle S., Jung G., Walden P. Self-MHC-restricted peptides recognized by an alloreactive T lymphocyte clone. J. Immunol. 157(2):1996;670-678.
27. Wang L., Lin J.-Y., Hsieh K.-H., Lin R.-W. Epicutaneous exposure of protein antigen induces a predominant Th-2 like response with high IgE production in mice. J. Immunol. 156:1996;4079-4082.
28. Herrick C.A., MacLeod H., Glusac E., Tigelaar R.E., Bottomly K. Th2 responses induced by epicutaneous or inhalational protein exposure are differentially dependent on IL-4. J. Clin. Invest. 105(6):2000;765-775.
29. Abbas A.K., Murphy K.M., Sher A. Functional diversity of helper T lymphocytes. Nature. 383(6603):1996;787-793.
30. Rappuoli R., Pizza M., Douce G., Dougan G. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol. Today. 20(11):1999;493-500.
31. Marinaro M., Staats H.F., Hiroi T. Mucosal adjuvant effect of cholera toxin in mice results from induction of T helper 2 (Th2) cells and IL-4. J. Immunol. 155(10):1995;4621-4629.
32. Mueller S.N., Jones C.M., Smith C.M., Heath W.R., Carbone F.R. Rapid cytotoxic T lymphocyte activation occurs in the draining lymph nodes after cutaneous herpes simplex virus infection as a result of early antigen presentation and not the presence of virus. J. Exp. Med. 195(5):2002;651-656.
33. Gately M.K., Renzetti L.M., Magram J.et al. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu. Rev. Immunol. 16:1998;495-521.
34. + T cells. J. Immunol. 162(6):1999;3256-3262.
35. Schmidt C.S., Mescher M.F. Peptide antigen priming of naive, but not memory, CD8 T cells requires a third signal that can be provided by IL-12. J. Immunol. 168(11):2002;5521-5529.
36. Gagliardi M.C., Sallusto F., Marinaro M., Langenkamp A., Lanzavecchia A., De Magistris M.T. Cholera toxin induces maturation of human dendritic cells and licenses them for Th2 priming. Eur. J. Immunol. 30(8):2000;2394-2403.
37. Glenn G.M., Taylor D.N., Li X., Frankel S., Montemarano A., Alving C.R. Transcutaneous immunization: a human vaccine delivery strategy using a patch. Nat. Med. 6(12):2000;1403-1406.
38. Beignon A.S., Briand J.P., Rappuoli R., Muller S., Partidos C.D. The LTR72 mutant of heat-labile enterotoxin of Escherichia coli enhances the ability of peptide antigens to elicit CD4(+) T cells and secrete gamma interferon after coapplication onto bare skin. Infect. Immun. 70(6):2002;3012-3019.
39. + T cells. Immunology. 105(2):2002;204-212.
40. + CTL induced by a single topical or transepithelial immunization via the buccal mucosa with measles virus nucleoprotein. J. Immunol. 167(1):2001;384-391.
41. Hengge U.R., Benninghoff B., Ruzicka T., Goos M. Topical immunomodulators - progress towards treating inflammation, infection, and cancer. Lancet Infect. Dis. 1(3):2001;189-198.
42. Wood L.C., Feingold K.R., Sequeira-Martin S.M., Elias P.M., Grunfeld C. Barrier function coordinately regulates epidermal IL-1 and IL-1 receptor antagonist mRNA levels. Exp. Dermatol. 3(2):1994;56-60.
43. Nickoloff B.J., Naidu Y. Perturbation of epidermal barrier function correlates with initiation of cytokine cascade in human skin. J. Am. Acad. Dermatol. 30(4):1994;535-546.
44. Stossel H., Koch F., Kampgen E.et al. Disappearance of certain acidic organelles (endosomes and Langerhans cell granules) accompanies loss of antigen processing capacity upon culture of epidermal Langerhans cells. J. Exp. Med. 172(5):1990;1471-1482.
45. Steinman R., Hoffman L., Pope M. Maturation and migration of cutaneous dendritic cells. J. Invest. Dermatol. 105(1 [Suppl.]):1995;2S-7S.
46. Holmgren J. Actions of cholera toxin and the prevention and treatment of cholera. Nature. 292(5822):1981;413-417.
47. Lycke N. The mechanism of cholera toxin adjuvanticity. Res. Immunol. 148(8-9):1997;504-520.
48. Yamamoto S., Kiyono H., Yamamoto M.et al. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc. Natl. Acad. Sci. U.S.A. 94(10):1997;5267-5272.
49. Holmgren J., Lycke N., Czerkinsky C. Cholera toxin and cholera B-subunit as oral-mucosal adjuvant and antigen vector systems. Vaccine. 11(12):1993;1179-1184.
50. Lycke N., Karlsson U., Sjolander A., Magnusson K.E. The adjuvant action of cholera toxin is associated with an increased intestinal permeability for luminal antigens. Scand. J. Immunol. 33(6):1991;691-698.
51. Wan Y., Lu L., Bramson J.L.et al. Dendritic cell-derived IL-12 is not required for the generation of cytotoxic, IFN-gamma-secreting, CD8(+) CTL in vivo. J. Immunol. 167(9):2001;5027-5033.
52. Simmons C.P., Mastroeni P., Fowler R.et al. MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants. J. Immunol. 163(12):1999;6502-6510.
53. van Ginkel F.W., Jackson R.J., Yuki Y., McGhee J.R. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J. Immunol. 165(9):2000;4778-4782.
54. Hemmi H., Takeuchi O., Kawai T.et al. A Toll-like receptor recognizes bacterial DNA. Nature. 408(6813):2000;740-745.
55. Hemmi H., Kaisho T., Takeuchi O.et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 3(2):2002;196-200.
56. Schuler-Thurner B., Schultz E.S., Berger T.G.et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J. Exp. Med. 195(10):2002;1279-1288.
57. Chen D., Weis K.F., Chu Q.et al. Epidermal powder immunization induces both cytotoxic T-lymphocyte and antibody responses to protein antigens of influenza and hepatitis B viruses. J. Virol. 75(23):2001;11630-11640.
58. Mikszta J.A., Alarcon J.B., Brittingham J.M., Sutter D.E., Pettis R.J., Harvey N.G. Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nat. Med. 8(4):2002;415-419.